Janux reclassifies director Eric Dobmeier from Class III to Class II to rebalance board classes

Janux Therapeutics, Inc.

On April 28, 2026, Eric Dobmeier resigned as Class III director and immediately reappointed as Class II director.
Change effective to achieve more equal balance among the three director classes on the Board.
Dobmeier's service deemed uninterrupted for vesting, equity awards, and compensation purposes.
Dobmeier continues on the Compensation Committee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.